Chidamide with the methotrexate, ifosfamide, etoposide, doxorubicin liposomes, and dexamethasone (MIEDD) regimen improves efficacy and safety in newly diagnosed primary CNS T-cell lymphoma
This trial demonstrates improved efficacy and safety in primary CNS T-cell lymphoma using chidamide and MIEDD regimen, suggesting a promising treatment approach.
Key Points
To evaluate the efficacy and safety of the MIEDD regimen combined with chidamide in newly diagnosed primary CNS T-cell lymphoma.
Patients received 3-6 cycles of the MIEDD regimen with or without chidamide at Beijing Tiantan Hospital.
Chidamide was administered at 30 mg orally twice a week during treatment.
Chemotherapy cycles lasted 21 days with specific dosing for methotrexate, ifosfamide, etoposide, doxorubicin liposomes, and dexamethasone.
8 out of 11 patients achieved complete remission after induction therapy.
The estimated progression-free survival rate was 68.2% at 2 years.
Most common adverse events included hypocytosis and gastrointestinal symptoms with no fatalities from toxicity.